OBDIPHY (OBesity DIgital-PHYsical Care Study) (OBDIPHY)

OBDIPHY (OBesity DIgital-PHYsical Care Study) - Effects of Digi-physical Care for Families

This is a prospective randomized controlled multicentre non-inferiority trial. The aim of this study to evaluate digi-physical care compared to regular physical/in person care and investigate if digi-physical care can be an equal or even better treatment alternative among families with children or adolescents living with obesity in Sweden. The study participants will either get treatment as usual or treatment as usual combined with digi-physical solution. The digi-physical solution includes thar half of the session is digital and they get an app where they can self-monitoring health data, have an overview over they treatment plan and easy communicate with theirs caregivers.

Study Overview

• Status: Completed
• Conditions: Obesity; Metabolic Syndrome; Pediatric Obesity; Weight Loss; Adolescent Obesity; Lifestyle Risk Reduction
• Intervention / Treatment: Behavioral: Digital-physical care; Behavioral: Treatment as usual

Detailed Description

This study is multi centre in three different county council in southwest of Sweden which include children and adolescents in the age of 10-16 year. The study participants will either get treatment as usual, which includes four in person session with healthcare professionals as doctor, nurse or dietitian (the control group) or treatment as usual combined with digi-physical solution (intervention group). The intervention group will beyond treatment as usual get a digital communication platform (including an app) where the patient has a good overview of their treatment plan, can report self-monitored health data as daily steps and weight once a week and monitor the daily work with their selected health goal. Everything in the app is individually tailored together with the patient. The patient with digi-physical care will also have assess to a chat for communication with their caregivers. The app has a high degree of authentication and classified as a journal system. Half of yearly treatment as usual sessions will be digital for the intervention group.

The digi-physical method of treatment is developed and based on the desire from the patient association HOBS (hälsa oberoende av storlek). In parts of Sweden people have long distance to the clinic which makes it difficult to be present at the treatment in-clinic sessions and the families loses many hours away from school and work. The null hypothesis is that digi-physical care will have a positive effect on BMI SDS, however inferior to treatment as usual.

In addition to evaluate that this new treatment alternative is safe will also ISO-BMI, weight development and metabolic risk factors be evaluated. The study does not include any extra blood samples or visits to the clinic thus everything is collected according to regular care programs. To evaluate the food intake and possible changes there will be three 24-h recalls, combined with riksmaten flex, performed. There will also be questions about their physical activity and a survey (PEDS-QL) for mental health. For a few volunteered patient families, approximate 15-20, will participate in semi-structured deep interviews.

• Study Type: Interventional
• Enrollment (Actual): 102
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Gothenburg, Sweden
    • Regionalt obesitascentrum
  • Halmstad, Sweden
    • Barnkliniken Halland
  • Kungsbacka, Sweden
    • Barnkliniken Halland
  • Malmo, Sweden
    • Överviktenheten Barn
  • Varberg, Sweden
    • Barnkliniken Halland

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 16 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• ISO-BMI 30 or above.

Exclusion Criteria:

• Lack of Swedish skills
• Patients potential for obesity surgery
• Patient with obesity syndrome

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Digital-physical care group; Combination of digital and physical care.	Behavioral: Digital-physical care; Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
Active Comparator: Treatment as usual.; Treatment as usual in accordance with national guidelines.	Behavioral: Treatment as usual; Four in person session at the center in a year.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in BMI standard deviation score at month 12.	The BMI standard-deviation score is a measure of the number of standard deviations from the population mean BMI (weight divided by height squared), matched for age and sex.	Baseline and month 12.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in BMI standard deviation score at month 6.	The BMI standard-deviation score is a measure of the number of standard deviations from the population mean BMI (weight divided by height squared), matched for age and sex.	Baseline and month 6.
Change from baseline in BMI standard deviation score at month 18.	The BMI standard-deviation score is a measure of the number of standard deviations from the population mean BMI (weight divided by height squared), matched for age and sex.	Baseline and month 18
Change from baseline in weight at month 3.	Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.	Baseline and month 3.
Change from baseline in weight at month 6.	Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.	Baseline and month 6.
Change from baseline in weight at month 9.	Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.	Baseline and month 9..
Change from baseline in weight at month 12.	Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.	Baseline and month 12.
Change from baseline in weight at month 18.	Weight in kilogram measure in clinic at the hospital scales from TANITA or self monitored at home on a Beurer BF 850 scale.	Baseline and month 18.
Change from baseline in waist circumference at 6 and 12 month.	Waist circumference measure in cm with measuring tape.	Baseline and month 6 and 12.
Change from baseline in waist circumference at 6 month.	Waist circumference measure in cm with measuring tape.	Baseline and month 6.
Change from baseline in blood pressure at12 month.	Bloodpressure in mm Hg, measured in right arm while sitting down after 5 minits of rest. It will be measured three times and then the mean of the two last measure will be calculated and reported.	Baseline and month 12.
Change from baseline in fasting insulin at 12 month.	Fasting insulin from blood sample measured in mU/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in fasting glucose at 12 month.	Fasting glucose from blood sample measured in mmol/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in HbA1c at 12 month.	HbA1c from blood sample measured in mmol/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in lever enzymes, ASAT, at 12 month.	ASAT from blood sample measured in µkat/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in lever enzymes, ALAT, at 12 month.	ALAT from blood sample measured in µkat/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in triglyceride at 12 month.	Triglyceride from blood sample measured in mmol/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in cholesterol at 12 month.	Cholesterol from blood sample measured in mmol/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in blood lipid, LDL, at 12 month.	LDL from blood sample measured in mmol/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in blood lipid, HDL, at 12 month.	HDL from blood sample measured in mmol/L. Analyzed according to standard routine.	Baseline and month 12.
Change from baseline in food intake according to Riksmaten Flex and 24-hour recalls in 12 month.	RiksmatenFlex and 24-hour recalls is a validated survey about food habits combined with three 24-hour interviews, where food intake the last 24 h are reported.	Baseline and month 12.
Change from baseline in amount of steps per day according to activity watch at week 52.	Amount of daily steps will be self-monitored with a sportsbuddy veryfit activity watch and then selfreported in to the study app. The mean of one weeks step will be colected at week 1, 26 and 52.	Baseline (week 1) and 52.
Change from baseline in amount of steps per day according to activity watch at week 26.	Amount of daily steps will be self-monitored with a sportsbuddy veryfit activity watch and then selfreported in to the study app. The mean of one weeks step will be collected at week 1, 26 and 52.	Baseline (week 1) and week 26.
Change from baseline in health-related quality of life according to PEDS-QL at 12 month	PEDS-QL is a valid questionaire for evaluating health-related quality of life used by the Swedish childhood obesity treatment register (BORIS). The child will answer if they never, almost never, sometimes, often or always has experience diffrent issues conserning their health.	Baseline and month 12.
Change from baseline in daily well-being on a 10 point VAS-scale at week 26.	Daily self reported well-being via a VAS-scale from 1-10 (1=worst feeling, 10=best feeling). The mean of one week reported data will be collected at week 1, 26 and 52.	Baseline (week 1), and week 26.
Change from baseline in daily well-being on a 10 point VAS-scale at week 52.	Daily self reported well-being via a VAS-scale from 1-10 (1=worst feeling, 10=best feeling). The mean of one week reported data will be collected at week 1, 26 and 52.	Baseline (week 1) and 52.
Thoughts on implementation from caregivers after a 12-month digital-physical care.	Survey about caregivers experience through implementation of digital care. Few easy questions about positive and negative aspects.	At month 12
Thoughts on implementation from patients after a 12-month digital-physical care.	Survey about patient experience through implementation of digital care. Few easy questions about positive and negative aspects and how they used the app.	At month 12
Semi-structured interviews for a deeper insight in the qualitative aspects concerning digital care.	Semi-structured interviews with 15-20 of the patient families inte the intervention group. The interview will proceed from open answer questions with the possibility to expand answers.	At month 12.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Report digital selfmonitored health data.	Evaluate the precentage of typ 2 diabetes patientens that reported self-monitored health data by the digital communication platform.	At 3 month.

Collaborators and Investigators

• Sponsor: Göteborg University
• Collaborators: Karolinska Institutet; Vastra Gotaland Region; Region Skane
• Investigators: Study Chair: Josefin Roswall, Region Halland

Study record dates

Study Major Dates

• Study Start (Actual): March 9, 2022
• Primary Completion (Actual): May 30, 2024
• Study Completion (Actual): May 30, 2024

Study Registration Dates

• First Submitted: December 7, 2021
• First Submitted That Met QC Criteria: February 9, 2022
• First Posted (Actual): February 21, 2022

Study Record Updates

• Last Update Posted (Actual): March 17, 2026
• Last Update Submitted That Met QC Criteria: March 13, 2026
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Body Weight Changes; Glucose Metabolism Disorders; Insulin Resistance; Hyperinsulinism; Overweight; Pathological Conditions, Signs and Symptoms; Behavior; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; Weight Loss; Metabolic Syndrome; Pediatric Obesity; Risk Reduction Behavior; Therapeutics
• Other Study ID Numbers: 276515

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No